- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 1.3MB)
Nusinersen – March 2022
Nusinersen: Solution for injection 12 mg in 5 mL; Spinraza®
Last updated
1 July 2022